Huons Group’s Huons Meditech recently announced on June 19, 2026, that its hyaluronic acid (HA)-based cross-linked filler product, 'Liporia HARA-L', has obtained medical device approval from the National Medical Products Administration (NMPA) of China.


Huons Meditech’s 'Liporia HARA-L' Filler Receives China NMPA Product Approval View original image

This marks the third approval for Huons Meditech in China, following the launches of 'Elravie Deep Line Plus' in 2015 and 'Elravie Deep Line-L' in 2019. 'Liporia HARA-L' is scheduled for official release in the fourth quarter of this year. Local distribution and sales will be handled by Xiangli Aesthetic, Huons Meditech’s partner in China. Huons Meditech expects to rapidly expand its market share in China by implementing differentiated local marketing strategies in collaboration with Xiangli Aesthetic.


'Liporia HARA-L', like Elravie Premier, is a domestic filler brand that utilizes Huons Meditech’s proprietary high-purity and high-stability hyaluronic acid production technology. It complies with the European Pharmacopoeia (EP) standards and uses the same sterile pharmaceutical-grade raw materials registered in Korea’s Drug Master File (DMF), which are also used for injections and eye drops.


'Liporia HARA-L' is a high-viscoelasticity product that maximizes the advantages of conventional monophasic and biphasic fillers. It features Huons Meditech’s proprietary 'HiVE (High Viscoelasticity)' technology and multiple purification processes, which increase cross-linking efficiency while minimizing the residual amount of the cross-linking agent (BDDE).


This recent product approval in China for 'Liporia HARA-L' marks its second overseas registration, following Thailand in February of last year. Huons Meditech plans to expand the number of countries where both its globally recognized hyaluronic acid filler Elravie Premier and 'Liporia HARA-L' are registered. The company aims to lay the groundwork for targeting the global market by establishing a diverse lineup of filler products.



Kang Minjong, CEO of Huons Meditech, stated, "With this Chinese approval for our hyaluronic acid filler, we have demonstrated the excellent quality and advanced technology of Huons Meditech’s products in the global market," adding, "We will continue to further expand our influence in overseas markets."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing